Attorney Docket No. 57778.8001.U

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

ete: May 0,2005

Rena lov

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RE APPLICATION OF: DAVIDSON, R. STEVEN

ART UNIT:

1615

APPLICATION NO.:

10/713,544

CONF. NO:

7965

FILED:

NOVEMBER 14, 2003

FOR: EDIBLE FILM FOR RELIEF OF COUGH OR

SYMPTOMS ASSOCIATED WITH

PHARYNGITIS

Supplemental Information Disclosure Statement Within Three Months of Application Filing or Before First Action - 37 C.F.R. § 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

1. **Timing of Submission**

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 C.F.R. § 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

\boxtimes	Copie	es of the f	rollowing	references	are e	nciosed	:
		All cited	referenc	es			

References marked by asterisks \Box

The following: References with Cite Nos. AZ through BA.

	Copies of the following references can be found in parent U.S. Application No. :					
		All cited references References marked by asterisks The following:				
⊠	This application was filed after 30 June 2003 and no copies of U.S. patents nor published applications are enclosed (See Notice of Deputy Commissioner Kunin on 11 July 2003).					
j	The following references are not in English. For each such reference, the undersigned has enclosed (i) a translation of the reference; (ii) a copy of a communication from a foreign patent office or International Searching Authority citing the reference, (iii) a copy of a reference which appears to be an English-language counterpart, or (iv) an English-language abstract for the reference prepared by a third party. Applicant has not verified that the translation, English-language counterpart or third-party abstract is an accurate representation of the teachings of the non-English reference, though, and reserves the right to demonstrate otherwise.					
		All cited references References marked by ampersands The following:				
Effect	of Info	rmation Disclosure Statement (37 C.F.R. § 1.97(h))				
that: examinesults cited in applicant to	(i) a sination s and the information the substitution of the subst	tion Disclosure Statement is not to be construed as a representation search has been made; (ii) additional information material to the of this application does not exist; (iii) the information, protocols, he like reported by third parties are accurate or enabling; or (iv) the ition is, or is considered to be, material to patentability. In addition, es not admit that any enclosed item of information constitutes prior bject invention and specifically reserves the right to demonstrate that erence is not prior art.				
Fee P	aymen	<u>t</u>				
		pelieved due because this Information Disclosure Statement is being ne mailing date of the first Office Action.				
		ant further submits that no fee is due in light of the following cation under 37 C.F.R. § 1.97(e) (check only one):				
		In accordance with 37 C.F.R. § 1.97(e)(1), the undersigned hereby states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; or				

3.

4.

In accordance with 37 C.F.R. § 1.97(e)(2), the undersigned hereby states that no item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c), more than three months prior to the filing of this statement.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2586.

5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,

Perkins Coie LLP

Date: May 10, 2005

Joseph P. Hamilton Registration No. 51,770

Correspondence Address:

Customer No. 34055
Perkins Coie LLP
Patent – LA
P.O. Box 1208
Seattle, WA 98111-1208
Phone: (310) 788-9900

Fax: (310) 788-3399

		·		COMPLETE IF KNOWN		
	INTERMATION PIECE COURT OF PE				10/713,544	
STATEMENT BY APPLICANT				Confirmation Number	7965	
				Filing Date	November 14, 2003	
				First Named Inventor	R. Steven Davidson	
				Group Art Unit	1615	
				Examiner Name	Not yet assigned	
Sheet	1	of		Attorney Docket No.	57778.8001.US01	

	**				U.S. PATENT DOCUMENTS			
Examiner Initials*	Cit	NUMBER (if knowr		Code	Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	A				Davidson	07/08/04		
	A١	AY US2004/0191302			Davidson	09/30/04		
			· · · · · ·					
		<u> </u>						
				FC	DREIGN PATENT DOCUMENTS			
Examiner Initials*	Cite No.			cation (ind Cod		Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
	AZ	WO	01/35934		LTS LOHMANN THERAPIE- SYSTEME AG	05/25/01		
					RT-NON PATENT LITERATURE			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.						
	ВА	Database WPI, Section Ch, Week 200375, Derwent Publications Ltd., London, GB; XP-002322049 & KR 2003 054 221 A (AEKYUNG IND CO LTD) July 2, 2003 (Abstract).						
-								

EXAMINER		DATE CONSIDERED			
1					
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not				
	considered. Include copy of this form with next communication to application(s).				